http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010508898-A

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
filingDate 2007-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2010-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2010508898-A
titleOfInvention Imaging of activated vascular endothelium using immunomagnetic MRI contrast agents
abstract Immunomagnetic nanoparticles are used as contrast agents for improved medical imaging such as magnetic resonance imaging (MRI). The present invention is directed to a method for producing a target MRI contrast agent from immunomagnetic particles and a method using such an MRI contrast agent. In general, such targeted MRI contrast agents provide improved relaxivity, improved signal to noise, targeting ability, and resistance to aggregation. Methods for making such MRI contrast agents generally control particle size better, and methods using such MRI contrast agents generally provide improved blood clearance rate and distribution To do. The ability to use contrast agents in MRI provides tools in the diagnosis and treatment of various disease states.
priorityDate 2006-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006102377-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003092029-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID55466
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24838310
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281839
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403975
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450360487
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3383
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450540594
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25464
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453759058
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID15894
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6432052

Total number of triples: 32.